Almaden Provides Update on Arbitration Procedure with Mexico GlobeNewswire July 28, 2025 VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) — Almaden Minerals Ltd. (“Almaden” or “the Company”; TSX: AMM; OTCQB: AAUAF) provides an update to the international arbitration proceedings (the “Claim”) under the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (“CPTPP”) with the United […]
Purpose Investments Inc. Announces Final July 2025 Distribution Rate for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund GlobeNewswire July 28, 2025 TORONTO, July 28, 2025 (GLOBE NEWSWIRE) — Purpose Investments Inc. announced today the final July 2025 distribution rates for Purpose High Interest
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis GlobeNewswire July 28, 2025 JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic Value GlobeNewswire July
Midland Announces Closing of $6.1 Million Private Placement with Strategic Investment from Centerra Gold GlobeNewswire July 28, 2025 MONTREAL, July 28, 2025 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland” or the “Corporation”) (TSX-V: MD) is pleased to announce the closing of a previously announced private placement (see press release dated July 22, 2025), for gross
NEW YORK, NY / ACCESS Newswire / July 28, 2025 / If you suffered a loss on your Neogen Corporation (NASDAQ:NEOG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neogen-corporation-lawsuit-submission-form?prid=158377&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NEW YORK, NY / ACCESS Newswire / July 28, 2025 / If you suffered a loss on your RxSight, Inc. (NASDAQ:RXST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=158378&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
NEW YORK, NY / ACCESS Newswire / July 28, 2025 / If you suffered a loss on your PepGen Inc. (NASDAQ:PEPG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=158383&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call
(ASX – Trade24:ATH.AX),(NASDAQ:ATHE), – ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ATH434 was Well-Tolerated with Favorable Safety Profile – – Data are Consistent with Phase 2 Double-Blind Trial and Support Advancement of ATH434
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy GlobeNewswire July 28, 2025 – ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy – – ATH434 was Well-Tolerated